Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
OncoCyte (OCX) just unveiled an announcement.
Oncocyte Corporation has appointed Andrea James as their new Chief Financial Officer and Principal Financial Officer, effective June 17, 2024. With a rich background in investor relations and corporate strategy, including senior roles at Axon Enterprise and strategic consultancy for Tesla, Inc., Ms. James brings a wealth of experience to the role. Her compensation includes a $325,000 base salary, with a potential annual bonus of 50%, along with comprehensive severance and equity terms. James has no familial ties to the company’s executives and her appointment is independent of any other agreements.
For detailed information about OCX stock, go to TipRanks’ Stock Analysis page.